
ExoMind™ is a non-invasive TMS option with specific FDA-cleared indications for major depressive disorder and, as an adjunct, adult obsessive-compulsive disorder. Amara also offers adjunctive ExoMind™ treatment for eligible patients ages 15–21 with major depressive disorder; patients ages 15–17 must be accompanied by a parent or legal guardian. Eligibility depends on diagnosis, age, and treatment history. For patients with these diagnosed conditions, feeling persistently overwhelmed, anxious, or stuck in a low mood affects far more than mental state; it shows up in sleep, focus, and overall quality of life. Everyday stress, anxiety without major depressive disorder, and sleep concerns on their own are not FDA-cleared ExoMind™ indications.
